Bacterial Conjunctivitis
📧 Sign up to get email alerts when something new happens for Bacterial Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-04-24FDA Approved: TOBRAMYCIN AND DEXAMETHASONE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for Tobramycin and Dexamethasone from Sandoz, updating the existing NDA for this ophthalmic anti…
-
FDA approval · 2020-03-30FDA Approved: MOXIFLOXACIN OPHTHALMIC SOLUTION — Original Application (Gland Pharma Limited)
The FDA approved Gland Pharma Limited's MOXIFLOXACIN OPHTHALMIC SOLUTION as an original ANDA, providing a generic ophthalmic antibiotic for …
-
FDA approval · 2020-02-07FDA Approved: NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for Maxitrol (neomycin sulfate, polymyxin B sulfate, and dexamethasone) by Bausch & Lomb Incorporate…
-
CLINICAL_TRIALS trial_result · 2019-10-28Clinical Trial Update: Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo [Phase 3]
Phase 3 trial comparing SHP640 to PVP-Iodine and placebo for bacterial conjunctivitis completed with posted results.
-
FDA approval · 2019-04-19FDA Approved: TOBRAMYCIN OPHTHALMIC SOLUTION — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Tobramycin Ophthalmic Solution from Alembic Pharmaceuticals Inc. under an original generic application (ANDA).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) [Phase 2]
Phase 2 trial comparing PRO-157 (pazufloxacin) to moxifloxacin and gatifloxacin for bacterial conjunctivitis has completed with posted resul…
-
FDA approval · 2019-02-13FDA Approved: MOXIFLOXACIN OPHTHALMIC SOLUTION — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals' original application for MOXIFLOXACIN OPHTHALMIC SOLUTION, a generic ophthalmic antibiotic, for the tr…
-
FDA approval · 2018-05-03FDA Approved: CIPROFLOXACIN HCL OPHTHALMIC — Original Application (Altaire Pharmaceuticals Inc.)
FDA approved the original application for ciprofloxacin hydrochloride ophthalmic solution from Altaire Pharmaceuticals, granting generic app…
-
FDA approval · 2017-12-18FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAXITROL (neomycin sulfate, polymyxin B sulfate and dexamethasone) from Novartis Pharmaceuticals…
-
FDA approval · 2017-10-04FDA Approved: MOXIFLOXACIN — Original Application (Aurobindo Pharma Limited)
FDA approved MOXIFLOXACIN ophthalmic solution from Aurobindo Pharma as an Original Application (ANDA), providing a generic option for bacter…
-
CLINICAL_TRIALS research · 2017-08-01Clinical Trial Update: Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers [Phase 1]
Phase 1 study updating the local pharmacokinetics of azithromycin ophthalmic solution in healthy volunteers, related to bacterial conjunctiv…
-
FDA approval · 2017-04-12FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAXITROL (neomycin sulfate, polymyxin B sulfate and dexamethasone) by Novartis Pharmaceuticals C…
-
FDA approval · 2017-03-14FDA Approved: VIGAMOX — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for Vigamox (moxifloxacin hydrochloride) submitted by Harrow Eye, LLC.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: AL-15469A for the Treatment of Bacterial Conjunctivitis [Phase 3]
The update indicates that a Phase 3 trial evaluating AL-15469A for bacterial conjunctivitis has completed. No trial results are disclosed in…
-
FDA approval · 2016-08-05FDA Approved: CILOXAN — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Ciloxan (ciprofloxacin hydrochloride) submitted by Sandoz Inc.
-
FDA approval · 2015-11-10FDA Approved: BESIVANCE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for BESIVANCE (besifloxacin) by Bausch & Lomb Americas Inc.
-
FDA label_change · 2015-10-06FDA Approved: MAXITROL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MAXITROL from Novartis Pharmaceuticals Corporation to update labeling for the combination ophtha…
-
CLINICAL_TRIALS trial_result · 2015-05-28Clinical Trial Update: Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis [Phase 2]
Phase 2 clinical trial evaluating Auriclosene for bacterial conjunctivitis has completed, reporting on its efficacy and safety.
-
FDA approval · 2015-05-28FDA Approved: MOXIFLOXACIN — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' MOXIFLOXACIN as a generic moxifloxacin ophthalmic solution; the approval covers its use for bacterial co…
-
CLINICAL_TRIALS trial_result · 2015-05-12Clinical Trial Update: An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients [Phase 3]
A Phase 3 trial compared safety and efficacy of VIGAMOX (moxifloxacin ophthalmic solution 0.5%) versus Ofloxacin ophthalmic solution 0.3% in…
-
CLINICAL_TRIALS withdrawal · 2014-12-11Clinical Trial Update: Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection [Phase 3]
A Phase 3 trial evaluating an antibiotic–steroid ophthalmic combination vs its individual components for ocular inflammation and infection w…
-
CLINICAL_TRIALS trial_result · 2014-09-17Clinical Trial Update: Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis [Phase 3]
Phase 3 trial evaluating besifloxacin ophthalmic suspension 0.6% for bacterial conjunctivitis was terminated, with results posted in 2014.
-
FDA label_change · 2014-09-05FDA Approved: BESIVANCE — Supplemental Application (Bausch & Lomb Americas Inc.)
The FDA approved a supplemental application for BESIVANCE (besifloxacin) from Bausch & Lomb Americas Inc., resulting in changes to the drug'…
-
CLINICAL_TRIALS trial_result · 2014-09-03Clinical Trial Update: Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis [Phase 3]
A Phase 3 trial comparing besifloxacin ophthalmic suspension with gatifloxacin ophthalmic solution in neonates with bacterial conjunctivitis…
-
FDA approval · 2014-04-30FDA Approved: BESIVANCE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for BESIVANCE (besifloxacin) from Bausch & Lomb Americas Inc.